Search
for
Sort by
Research 151–180 of 325
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
- Neo-synthesis of estrogenic or androgenic neurosteroids determine whether long-term potentiation or depression is induced in hippocampus of male rat
- Systematic Review of Psychological Interventions for Quality of Life, Mental Health, and Hair Growth in Alopecia Areata and Scarring Alopecia
- Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data
- Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
- Stem Cell Therapies for Epidermolysis Bullosa Treatment
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- New developments in the molecular treatment of ichthyosis: review of the literature
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
- The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
- [Retracted] Fibroblasts in Scar Formation: Biology and Clinical Translation
- Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals
- 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort
- Bullying in persons with skin diseases
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Influence of Recombinant Codon-Optimized Plasmid DNA Encoding VEGF and FGF2 on Co-Induction of Angiogenesis
- New developments in the treatment of systemic lupus erythematosus
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- The Pressurized Skin: A Review on the Pathological Effect of Mechanical Pressure on the Skin from the Cellular Perspective
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis